Recursion to Present Updated Clinical Data from Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis
核心洞察
Recursion will present new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (搜索) during a webinar on December 8, 2025.
The webinar will focus on updated safety and efficacy data for the allosteric MEK1/2 (搜索) inhibitor REC-4881 as monotherapy in FAP (搜索) patients.
Key clinical experts from Recursion and academic institutions will present the findings, including leadership from University of Utah and Memorial Sloan Kettering Cancer Center.
Recursion (Nasdaq: RXRX), a clinical stage TechBio company, announced it will present new clinical data from its ongoing TUPELO Phase 1b/2 trial evaluating REC-4881 in familial adenomatous polyposis (搜索) (FAP (搜索)) during a company webinar scheduled for December 8, 2025. The presentation will focus on updated safety and efficacy results for the allosteric MEK1/2 (搜索) inhibitor as monotherapy in FAP patients.
Clinical Trial Update
The webinar, titled "Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 (搜索) Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (搜索) (FAP (搜索)): Updated Safety and Efficacy," will be held at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The presentation will be streamed live on Recursion's X, LinkedIn, and YouTube accounts.
Expert Panel
The webinar will feature a distinguished panel of presenters including:
- Najat Khan, Ph.D., Chief R&D and Chief Commercial Officer and incoming CEO and President at Recursion
- David Mauro, M.D., Ph.D., Chief Medical Officer at Recursion
- Beth Bruckheimer, Ph.D., Vice President of Clinical Development at Recursion
- Jessica Stout, D.O., Assistant Clinical Professor at University of Utah School of Medicine
- Alfred Cohen, M.D., Former CMO of Cancer Prevention Pharmaceuticals and Prior Chief of Colorectal Service at Memorial Sloan Kettering Cancer Center
Company Platform
Recursion operates through its Recursion OS platform, which continuously generates one of the world's largest proprietary biological and chemical datasets. The company leverages sophisticated machine-learning algorithms to analyze trillions of searchable relationships across biology and chemistry. The platform supports massive experimental scale with up to millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world.
The Salt Lake City-headquartered company is a founding member of BioHive, the Utah life sciences industry collective, and maintains additional offices in Montréal, New York, London, and the Oxford area.